Roche Pharmaceutical Development and Sales Overview
Lunsumio (mosunetuzumab, CD20 x CD3, RG7828)
Bispecific anti-CD20/CD3 antibody engaging T and B cells simultaneously
Indication
1L DLBCL & 2L DLBCL following 1L induction
Relapsed or refractory 2L+ FL
Phase/study
# of patients
Design
Primary endpoint
Status
CT Identifier
◉
"
Phase I
N=92+80 (cohort C)
Cohort A: Lunsumio monotherapy (after a response to prior systemic
chemotherapy)
Cohort B: Lunsumio monotherapy (1L treatment in elderly/frail)
Cohort C: Lunsumio SC plus Polivy in 1L elderly/unfit
▪ Safety/tolerability and response
FPI Q2 2019 - Cohort B
FPI Q3 2019 - Cohort A
Initial data presented at ASH 2020 (Cohort B)
Cohort C: FPI Q1 2021
NCT03677154
Phase lb
N=27
Lunsumio plus lenalidomide safety run-in for phase III
Lunsumio SC plus lenalidomide
■ Safety/tolerability and response
FPI Q3 2020
Initial data presented at ASH 2021
FL-follicular lymphoma; DLBCL-diffuse large B cell lymphoma; r/r-relapsed/refractory; SC=subcutaneous; ASH-American Society of Hematology
NCT04246086
Roche
81
OncologyView entire presentation